Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation
This article was originally published in The Pink Sheet Daily
Executive Summary
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
You may also be interested in...
Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.